Objective to detect the ABL point mutations in chronic myeloid leukemia (CML) patients treated with imatinib by denaturing high-performance liquid chromatography (DHPLC).
目的应用变性高效液相色谱(DHPLC)检测伊马替尼治疗后慢性髓性白血病(CML)患者ABL激酶区点突变。
In BCR-ABL fusion gene negative myeloproliferative diseases, the discovery of JAK2V617F point mutation is an important landmark.
在BCR- ABL阴性的骨髓增殖性疾病的发病机制中，JAK2V 617 F点突变的发现是一个重大的突破。
In BCR-ABL fusion gene negative myeloproliferative diseases, the discovery of JAK2V617F point mutation is an important landmark.
在BCR- ABL阴性的骨髓增殖性疾病的发病机制中，JAK2V 617 F点突变的发现是一个重大的突破。
应用推荐